The Antimicrobial Resistance Network (AMRNet): Clinical data and reports
The AMRNet surveillance program collects antimicrobial resistance data submitted by Canadian laboratories.
- Last updated: 2026-01-26
On this page
Antimicrobial Resistance (AMR) data
The Public Health Agency of Canada’s AMRNet program collects antimicrobial resistance data submitted by laboratories from provinces and territories across Canada. Currently results include data submitted by laboratories in British Columbia, Alberta, Saskatchewan, Ontario, New Brunswick, Newfoundland and Labrador, Northwest Territories and Prince Edward Island.
The figures and tables below summarize antimicrobial resistance trends among clinical isolates from blood and urine. The antibiograms (Figure 1) include only 2024 data, while the graphs (Figure 2) includes data from 2020–2024. Please see the Methods and limitations section below for a detailed description of the data included in these charts.
Figure 1. Antibiogram of the susceptibility (%) of bacteria to select antibiotics (2024)
Antibiogram of the percent susceptibility of bacteria to select antibiotics, in blood (2024)
Figure 1: Text description
Figure 2. Susceptibility (%) of bacteria to select antibiotics over time (2020–2024)
Hover over the lines by year to display more information. Click the antibiotic names to add or remove lines.
Figure 2: Percent susceptibility of bacteria to select antibiotics over time (2020–2024)
Figure 2: Text description
Methods and limitations
AMRNet is a national surveillance program currently under development. AMRNet collects phenotypic susceptibility data on clinical isolates from both inpatient and outpatient settings.
Data from participating laboratories may not be representative of all Canadian regions. Different laboratories use different techniques for antimicrobial susceptibility testing. Data on specific bacteria-antimicrobial combinations are not available from all laboratories.
To reduce the likelihood of bias in results, AMRNet uses the following reporting criteria for antibiograms:
- Data must represent laboratory-bacteria-specimen type combinations where at least 85% of isolates are tested or reported for a given antimicrobial.
- Data must represent isolates from at least three provinces/territories.
- Data must represent at least 30 isolates.
Fields that do not meet these requirements are indicated as N/A in Figure 2.
Where possible, duplicates, as defined by the Clinical & Laboratory Standards Institute, were removed for all analyses presented here.
Disclaimer
Data presented are for research and surveillance purposes and should not be used to direct clinical therapy.
Reports and publications
- Overview of AMRNet surveillance program in the Canada Communicable Disease Report (CCDR) publication
- AMRNet data presented in the 2023 Canadian Antimicrobial Resistance Surveillance System (CARSS) Report
Related links
- Information on antimicrobial use and antimicrobial resistance in foodborne bacteria along the food chain can be found on the Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS) website.
- The Canadian Nosocomial Infection Surveillance Program (CNISP) monitors healthcare-associated infections at participating acute-care hospitals across Canada.
- The Canadian Antimicrobial Resistance Alliance (CARA) is a research group dedicated to the study of medical microbiology/infectious diseases issues with special interest in infections caused by antimicrobial resistant pathogens as well as antimicrobial usage in Canada.
- Date modified: